Curis, Inc. (NASDAQ:CRIS) has received a consensus recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $6.67.

A number of equities research analysts have recently issued reports on CRIS shares. Cowen and Company restated a “buy” rating on shares of Curis in a report on Wednesday, March 22nd. Zacks Investment Research cut Curis from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Finally, ValuEngine upgraded Curis from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd.

In other news, Director James R. Mcnab sold 76,276 shares of Curis stock in a transaction that occurred on Friday, May 5th. The shares were sold at an average price of $2.04, for a total value of $155,603.04. Following the completion of the sale, the director now directly owns 879,688 shares in the company, valued at $1,794,563.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director James R. Mcnab sold 146,694 shares of Curis stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $2.61, for a total transaction of $382,871.34. Following the completion of the sale, the director now owns 912,426 shares of the company’s stock, valued at $2,381,431.86. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 450,000 shares of company stock valued at $1,101,973. Corporate insiders own 4.07% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. State Street Corp increased its stake in Curis by 5.5% in the fourth quarter. State Street Corp now owns 1,663,980 shares of the biotechnology company’s stock worth $5,125,000 after buying an additional 86,308 shares during the last quarter. Two Sigma Investments LP acquired a new stake in Curis during the fourth quarter worth $183,000. Perceptive Advisors LLC acquired a new stake in Curis during the first quarter worth $1,390,000. Janney Montgomery Scott LLC increased its stake in Curis by 11.1% in the first quarter. Janney Montgomery Scott LLC now owns 123,644 shares of the biotechnology company’s stock worth $344,000 after buying an additional 12,344 shares during the last quarter. Finally, Teachers Advisors LLC increased its stake in Curis by 62.5% in the fourth quarter. Teachers Advisors LLC now owns 368,278 shares of the biotechnology company’s stock worth $1,134,000 after buying an additional 141,712 shares during the last quarter. Institutional investors own 51.63% of the company’s stock.

Curis (NASDAQ:CRIS) traded down 3.74% during trading on Tuesday, reaching $2.06. The company’s stock had a trading volume of 60,762 shares. The firm’s 50-day moving average is $1.82 and its 200-day moving average is $2.50. The stock’s market cap is $296.17 million. Curis has a 52-week low of $1.56 and a 52-week high of $3.72.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.02. Curis had a negative return on equity of 163.29% and a negative net margin of 841.05%. The business had revenue of $2.13 million for the quarter, compared to the consensus estimate of $1.98 million. During the same quarter in the previous year, the business posted ($0.07) EPS. The company’s revenue for the quarter was up 23.1% on a year-over-year basis. Equities research analysts forecast that Curis will post ($0.40) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/18/curis-inc-cris-given-consensus-rating-of-buy-by-analysts.html.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.